MEREO BIOPHARMA GROUP PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.935 USD | -1.84% |
|
-9.33% | +28.35% |
Presenter SpeechDenise Scots-Knight (Executives)Good morning. My name is Denise Scots-Knight, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Calendar
2024-09-16
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.349
GBP
Average target price
4.959
GBP
Spread / Average Target
+111.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.35% | 419M | |
| +10.75% | 115B | |
| +12.16% | 106B | |
| -4.36% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -12.92% | 17.56B | |
| -40.50% | 17.32B | |
| +6.51% | 14.03B | |
| +31.06% | 12.13B |
- Stock Market
- Equities
- MREO Stock
- News Mereo BioPharma Group plc
- Transcript : Mereo BioPharma Group plc - Special Call
